Medical Science Liaison Director
Rhythm Pharmaceuticals
Medical Science Liaison Director
Rhythm Pharmaceuticals
Commercializes MC4R-targeted therapies for rare obesity
Company Overview
Rhythm is a global, commercial-stage biopharmaceutical company committed to transforming the lives of patients and their families living with rare neuroendocrine diseases. We develop medicines for previously untreatable or undertreated diseases and provide meaningful support for healthcare providers and patients and their families. We recognize the courage it takes for patients and their caregivers to begin their journey of advocacy to find the answers they need. Their courage inspires us to challenge convention, ask bold questions and seek answers for them. Every day, we strive for excellence through our willingness to adapt, learn, and our tenacity to overcome barriers, together.
Commercializes MC4R-targeted therapies for rare obesity
Rhythm Pharmaceuticals focuses on developing therapies for rare neuroendocrine genetic obesity disorders, led by IMCIVREE (setmelanotide). IMCIVREE is an MC4R agonist that restores signaling in the MC4R pathway to curb hunger and regulate energy use; it is FDA, EC, and MHRA approved for Bardet-Biedl syndrome and certain POMC/PCSK1/LEPR deficiencies in patients aged 2 and older, with revenue from global sales. The company differentiates itself by pursuing precision medicine for MC4R pathway diseases and advancing additional MC4R programs like bivamelagon and RM-718. Rhythm’s goal is to broaden access to MC4R-targeted therapies for rare patient populations and grow its pipeline toward sustainable commercialization.
Explore more opportunities at Rhythm Pharmaceuticals